All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML
During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke to Ali Bazarbachi, American University of Beirut, Beirut, LB. We asked, How can MRD testing be put to best use in AML?
How can MRD testing be put to best use in AML?
In this video, Bazarbachi explains the role of measurable residual disease (MRD) monitoring. The persistence of MRD is a strong predictor for relapse following therapy in AML.
Ali Bazarbachi | EBMT 2019 | Maintenance treatment after stem cell transplantation
At the 45th Annual Meeting of the EBMT, Ali Bazarbachi discusses maintenance treatment after stem cell transplantation
Is a TP53 mutation always a poor prognostic marker for transplantation in AML?
During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke to Justin Loke, University of Birmingham, Birmingham,...
Subscribe to get the best content related to AML delivered to your inbox